Press release
Travere Therapeutics "Sparsentan" Market size expansion of Several Folds by 2032
Are you interested in finding out the projected market size of Sparsentan in 2032? Sparsentan Market Forecast https://www.delveinsight.com/report-store/sparsentan-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
The Sparsentan Market Report offers projected sales forecasts for Sparsentan for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
Travere Therapeutics Sparsentan is serving as a beacon of hope for the patients suffering from the Focal Segmental Glomerulosclerosis.
What is a Sparsentan Prescribed for?
Sparsentan, currently in Phase 3 development, is an innovative small-molecule candidate intended for the treatment of focal segmental glomerulosclerosis (FSGS). FSGS is a form of kidney damage affecting the glomeruli (filter units), attributed to various causes, frequently resulting in a decline in kidney function and the advancement toward kidney failure. Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have designated orphan drug status to sparsentan for the treatment of FSGS.
The report extensively covers the details and developments related to Sparsentan, capturing important highlights on developmental pipeline, regulatory status and special designations of Sparsentan, route of administration, safety and efficacy details.
Sparsentan Market Assessment
This report provides a detailed market assessment of Sparsentan for Focal Segmental Glomerulosclerosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.
Sparsentan Clinical Assessment
The report provides the clinical trials information of Sparsentan for Focal Segmental Glomerulosclerosis covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Do you know your drug's competitive positioning against Sparsentan? Sparsentan Drugs Insights https://www.delveinsight.com/sample-request/sparsentan-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Sparsentan Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Sparsentan.
Sparsentan Market Size in the US
A dedicated section of the report focuses on the expected market size of Sparsentan for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.
Key Highlights of Sparsentan:
• The report contains forecasted sales of Sparsentan for indication till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Focal Segmental Glomerulosclerosis.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for Sparsentan in Focal Segmental Glomerulosclerosis.
Stay ahead in competition by leveraging insights on Sparsentan market Report: Download Sparsentan Market Report https://www.delveinsight.com/sample-request/sparsentan-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Why you should buy Sparsentan Market Report:
• The report provides future market assessments for Sparsentan for Focal Segmental Glomerulosclerosis in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading Sparsentan for Focal Segmental Glomerulosclerosis forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Sparsentan
• Discover the competitive landscape of Sparsentan through 7MM
• Get a Thorough Analysis of the Sparsentan Development pipeline, Safety & Efficacy of the Sparsentan, and ROA
• Thorough Sparsentan market forecast will help understand how drug is competing with other emerging Sparsentan
• Get analysis of the Sparsentan clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints
Related Reports By DelveInsight:
Focal Segmental Glomerulosclerosis Pipeline https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Focal Segmental Glomerulosclerosis Pipeline Insight, 2024" report provides comprehensive insights about 15+ companies and 18+ pipeline drugs in the Focal Segmental Glomerulosclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The key Focal Segmental Glomerulosclerosis companies developing therapies include - Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4, and others.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Top Services Offered By DelveInsight:
Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry. https://www.delveinsight.com/case-study/r-and-d-landscape-assessment
Recent Reports Offered By DelveInsight:
Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.
Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Travere Therapeutics "Sparsentan" Market size expansion of Several Folds by 2032 here
News-ID: 3396003 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Sparsentan
Focal Segmental Glomerulosclerosis Drugs Market to Reach US$ 3.55B by 2033 | CAG …
The Focal Segmental Glomerulosclerosis Drugs Market reached US$ 972.55 million in 2024 and is expected to reach US$ 3,550.15 million by 2033, growing at a CAGR of 15.7% from 2025 to 2033. The market is gaining strong momentum as advancements in understanding FSGS pathophysiology drive development of targeted therapies, increased awareness of rare kidney diseases, and rising investments in clinical trials for novel treatments addressing primary and genetic forms.
Growth is…
Focal Segmental Glomerulosclerosis Market to Experience Notable Growth in Foreca …
DelveInsight's "Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Focal Segmental Glomerulosclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Focal Segmental Glomerulosclerosis Market…
Focal Segmental Glomerulosclerosis Market Trends Point to Steady Growth Ahead by …
The Key Focal Segmental Glomerulosclerosis Companies in the market include - Evergreen Therapeutics, Certa Therapeutics, River 3 Renal Corp, Boehringer Ingelheim, Dimerix Bioscience, Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others.
DelveInsight's "Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Focal…
Focal Segmental Glomerulosclerosis Pipeline Insight 2025: 18+ Emerging Therapies …
DelveInsight's "Focal Segmental Glomerulosclerosis - Pipeline Insight, 2025" reviews more than 18+ therapies in development for focal segmental glomerulosclerosis (FSGS), a rare and severe form of chronic kidney disease often leading to end-stage renal failure. Current treatment strategies, including corticosteroids, calcineurin inhibitors, and supportive therapies, provide limited efficacy, leaving a high unmet need in the FSGS treatment market.
The FSGS pipeline is broadening with novel mechanisms of action, including endothelin receptor…
Focal Segmental Glomerulosclerosis Market to Reach USD 1.62 Billion by 2034
Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disorder characterized by scarring (sclerosis) in parts of the glomeruli, which filter blood in the kidneys. This condition leads to proteinuria, nephrotic syndrome, and progressive renal failure if left untreated. FSGS can be primary (idiopathic) or secondary (linked to genetic mutations, obesity, hypertension, or infections).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71062
Over the past decade, FSGS has gained increased recognition…
Propulsion of IgA Nephropathy Clinical Trial Pipeline as Novel and Extensive 30+ …
DelveInsight's, "IgA Nephropathy Pipeline Insight, 2023," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy pipeline drug profiles, including IgA Nephropathy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the IgA Nephropathy…
